109 related articles for article (PubMed ID: 36165000)
1. A comprehensive gene expression profile analysis of prostate cancer cells resistant to paclitaxel and the potent target to reverse resistance.
Che P; Jiang S; Zhang W; Zhu H; Hu D; Wang D
Hum Exp Toxicol; 2022; 41():9603271221129854. PubMed ID: 36165000
[No Abstract] [Full Text] [Related]
2. Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1.
Li X; Han X; Wei P; Yang J; Sun J
Cancer Biol Ther; 2020 May; 21(5):452-462. PubMed ID: 32089062
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines.
Samli H; Samli M; Vatansever B; Ardicli S; Aztopal N; Dincel D; Sahin A; Balci F
World J Urol; 2019 Jun; 37(6):1117-1126. PubMed ID: 30244336
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
[TBL] [Abstract][Full Text] [Related]
5. MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression.
Fujita Y; Kojima K; Ohhashi R; Hamada N; Nozawa Y; Kitamoto A; Sato A; Kondo S; Kojima T; Deguchi T; Ito M
J Biol Chem; 2010 Jun; 285(25):19076-84. PubMed ID: 20406806
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the sphingolipid rheostat is involved in paclitaxel resistance of the human prostate cancer cell line PC3-PR.
Aoyama Y; Sobue S; Mizutani N; Inoue C; Kawamoto Y; Nishizawa Y; Ichihara M; Kyogashima M; Suzuki M; Nozawa Y; Murate T
Biochem Biophys Res Commun; 2017 Apr; 486(2):551-557. PubMed ID: 28322796
[TBL] [Abstract][Full Text] [Related]
7. Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation.
Flores ML; Castilla C; Gasca J; Medina R; Pérez-Valderrama B; Romero F; Japón MA; Sáez C
Mol Cancer Ther; 2016 Jul; 15(7):1713-25. PubMed ID: 27196755
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of PER3 reverses paclitaxel resistance of prostate cancer cells by inhibiting the Notch pathway.
Cai DW; Chen D; Sun SP; Liu ZJ; Liu F; Xian SZ; Wu PS; Kong GQ
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2572-2579. PubMed ID: 29771413
[TBL] [Abstract][Full Text] [Related]
9. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
[No Abstract] [Full Text] [Related]
10. Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Wang W; Wang L; Mizokami A; Shi J; Zou C; Dai J; Keller ET; Lu Y; Zhang J
Chin J Cancer; 2017 Mar; 36(1):35. PubMed ID: 28356132
[TBL] [Abstract][Full Text] [Related]
11. LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis.
Leng W; Liu Q; Zhang S; Sun D; Guo Y
Cancer Biol Ther; 2020 Nov; 21(11):1072-1080. PubMed ID: 33138677
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel.
Sobue S; Mizutani N; Aoyama Y; Kawamoto Y; Suzuki M; Nozawa Y; Ichihara M; Murate T
Biochem Biophys Res Commun; 2016 Oct; 479(4):808-813. PubMed ID: 27687545
[TBL] [Abstract][Full Text] [Related]
13. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
Kojima K; Fujita Y; Nozawa Y; Deguchi T; Ito M
Prostate; 2010 Oct; 70(14):1501-12. PubMed ID: 20687223
[TBL] [Abstract][Full Text] [Related]
14. Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.
Xue D; Lu H; Xu HY; Zhou CX; He XZ
J Cell Mol Med; 2018 Jun; 22(6):3223-3237. PubMed ID: 29633510
[TBL] [Abstract][Full Text] [Related]
15. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
[TBL] [Abstract][Full Text] [Related]
16. Establishment of new intraperitoneal paclitaxel-resistant gastric cancer cell lines and comprehensive gene expression analysis.
Murakami H; Ito S; Tanaka H; Kondo E; Kodera Y; Nakanishi H
Anticancer Res; 2013 Oct; 33(10):4299-307. PubMed ID: 24122996
[TBL] [Abstract][Full Text] [Related]
17. Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis.
Xue YN; Yu BB; Liu YN; Guo R; Li JL; Zhang LC; Su J; Sun LK; Li Y
Prostate; 2019 May; 79(6):647-656. PubMed ID: 30714183
[TBL] [Abstract][Full Text] [Related]
18. Lovastatin enhances chemosensitivity of paclitaxel-resistant prostate cancer cells through inhibition of CYP2C8.
Li Y; Chen S; Zhu J; Zheng C; Wu M; Xue L; He G; Fu S; Deng X
Biochem Biophys Res Commun; 2022 Jan; 589():85-91. PubMed ID: 34896780
[TBL] [Abstract][Full Text] [Related]
19. The role of the SHH gene in prostate cancer cell resistance to paclitaxel.
Statkiewicz M; Maryan N; Lipiec A; Grecka E; Grygorowicz MA; Omiotek M; Gorska A; Mikula M; Malecki M
Prostate; 2014 Aug; 74(11):1142-52. PubMed ID: 24925370
[TBL] [Abstract][Full Text] [Related]
20. A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer.
Byun WS; Jin M; Yu J; Kim WK; Song J; Chung HJ; Jeong LS; Lee SK
Biochem Pharmacol; 2018 Dec; 158():84-94. PubMed ID: 30292755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
